A Single Dose of BNT162b2 mRNA Vaccine Induces Airway Immunity in SARS-CoV-2 Naive and recovered COVID-19 subjects.

ABSTRACT:

Background

Mucosal antibodies can prevent virus entry and replication in mucosal epithelial cells and hence virus shedding. Parenteral booster injection of a vaccine against a mucosal pathogen promotes stronger mucosal immune responses following prior mucosal infection compared to injections of a parenteral vaccine in a mucosally naive subject. We investigated whether this was also the case for the BNT162b2 COVID-19 mRNA vaccine.

Methods

Twenty recovered COVID-19 subjects (RCS) and 23 SARS-CoV-2 naive subjects were vaccinated with respectively one and two doses of the BNT162b2 COVID-19 vaccine. Nasal Epithelial Lining Fluid (NELF) and plasma were collected before and after vaccination and assessed for Immunoglobulin (Ig)G and IgA antibody levels to Spike and for their abilit

SUBMITTER: Martinuzzi E 

PROVIDER: S-EPMC9129216 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature